Mesoblast Limited (NASDAQ:MESO) Q3 Earnings: Navigating Losses with Strategic Growth in Cell Therapy

Font: Financial Modeling Prep  • Aug 27, 2026

• Mesoblast Limited exceeded quarterly revenue estimates, reporting $69.50 million, and projects strong full-year revenue growth to $120.00 million for fiscal year 2026.
• Despite revenue performance, the company reported an earnings per share (EPS) of -$0.15, missing consensus estimates, and a negative Price-to-Earnings (P/E) ratio of -22.88, indicating a net loss.
• Demonstrating improved financial discipline, Mesoblast reduced its net loss after tax by 44% to $57.50 million and ended the fiscal year with $103.00 million in cash, while planning to expand its key product RYONCIL to the adult market.

Mesoblast Limited (NASDAQ: MESO) is a global biotechnology company that develops cellular medicines for inflammatory diseases. Its main product, RYONCIL, is the first and only FDA-approved mesenchymal stromal cell product in the United States. It is used to treat children with a condition called steroid-refractory acute graft-versus-host disease.

On August 26, 2026, Mesoblast reported its quarterly earnings. The company announced revenue of $69.50 million for the quarter, which surpassed the analyst estimate of $66.97 million. This performance contributes to the substantial full-year revenue growth to $120.00 million for the fiscal year 2026, as highlighted by GlobeNewswire.

However, the company’s earnings per share (EPS) came in at -$0.15, missing the consensus estimate of -$0.11. An EPS shows how much profit a company makes for each share of its stock. A negative number means the company had a net loss. This aligns with Mesoblast's Price-to-Earnings (P/E) ratio of -22.88, which also indicates negative earnings.

Despite the quarterly loss, Mesoblast shows signs of improving financial discipline. The company successfully reduced its net loss after tax by 44% to $57.50 million for the full year. It also significantly decreased its cash burn, or the rate at which it spends money, ending the fiscal year with $103.00 million in cash.

Operationally, the company continues to see growing market adoption for RYONCIL. CEO Dr. Silviu Itescu notes plans to expand the therapy's use to adults, which would target a significantly larger market. This growth is part of the company's focus on disciplined capital allocation while investing in high-value opportunities.